- Home
- AQB vs VRAX Comparison
AQB vs VRAX Comparison
Compare AQB & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AQB | VRAX |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 2.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | AQB | VRAX |
|---|---|---|
| Price | $1.03 | $0.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 45.4K | ★ 460.8K |
| Earning Date | 10-28-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,986.00 |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $0.30 |
| 52 Week High | $2.95 | $2.52 |
Technical Indicators
Market Signals| Indicator | AQB | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 57.27 | 39.56 |
| Support Level | $0.87 | $0.30 |
| Resistance Level | $1.09 | $0.37 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 76.92 | 11.42 |
Price Performance
Historical ComparisonAbout AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).